• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications don't work for a majority of people suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform for digital devices that transforms passively acquired smartphone sensor data into personalized micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to understand their feature predictors and uncover distinct characteristics that can be used to predict changes in mood over time.

Predictors of Mood

Depression is among the most prevalent causes of mental illness.1 Yet, only half of those who have the condition receive treatment1. To improve the outcomes, doctors must be able identify and treat patients who are the most likely to benefit from certain treatments.

A customized depression treatment plan can aid. Utilizing sensors for mobile phones as well as an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new holistic ways to treat depression to predict which patients will benefit from the treatments they receive. With two grants awarded totaling over $10 million, they will use these technologies to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research into predictors of depression treatment effectiveness has been focused on sociodemographic and clinical characteristics. These include factors that affect the demographics such as age, gender and education, clinical characteristics including symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these aspects can be predicted from the information available in medical records, few studies have employed longitudinal data to study predictors of mood in individuals. They have not taken into account the fact that moods vary significantly between individuals. Therefore, it is essential to develop methods that allow for the identification of the individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to identify patterns of behaviour and emotions that are unique to each person.

The team also developed a machine-learning algorithm that can model dynamic predictors for each person's depression mood. The algorithm integrates the individual differences to produce a unique "digital genotype" for each participant.

This digital phenotype has been correlated with CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was weak, however (Pearson r = 0,08; P-value adjusted by BH 3.55 x 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is a leading cause of disability around the world1, but it is often not properly diagnosed and treated. In addition, a lack of effective interventions and stigma associated with depression disorders hinder many people from seeking help.

To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. However, current prediction methods depend on the clinical interview which is not reliable and only detects a small variety of characteristics associated with depression.2

Machine learning can enhance the accuracy of the diagnosis and treatment of inpatient depression treatment centers - click through the following post - by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements and capture a wide range of distinct behaviors and patterns that are difficult to capture through interviews.

The study enrolled University of California Los Angeles (UCLA) students with moderate to severe depressive symptoms. participating in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were directed to online assistance or in-person clinics depending on their depression severity. Patients with a CAT DI score of 35 65 were assigned online support via the help of a peer coach. those who scored 75 patients were referred to psychotherapy in person.

At the beginning of the interview, participants were asked a series of questions about their personal characteristics and psychosocial traits. These included age, sex education, work, and financial status; whether they were partnered, divorced or single; the frequency of suicidal ideation, intent or attempts; and the frequency at the frequency they consumed alcohol. Participants also rated their degree of depression severity on a 0-100 scale using the CAT-DI. The CAT-DI tests were conducted every other week for the participants that received online support, and weekly for those receiving in-person support.

Predictors of the Reaction to Treatment

Personalized depression treatment is currently a major research area, and many studies aim to identify predictors that allow clinicians to identify the most effective drugs for each person. Pharmacogenetics, for instance, uncovers genetic variations that affect how the human body metabolizes drugs. This enables doctors to choose the medications that are most likely to work best for each patient, minimizing the time and effort involved in trials and errors, while eliminating any side effects that could otherwise slow progress.

Another promising approach is building models for prediction using multiple data sources, such as data from clinical studies and neural imaging data. These models can then be used to identify the most appropriate combination of variables that are predictive of a particular outcome, such as whether or not a medication will improve symptoms and mood. These models can also be used to predict the response of a patient to a treatment they are currently receiving, allowing doctors to maximize the effectiveness of the treatment currently being administered.

A new generation uses machine learning methods such as the supervised and classification algorithms, regularized logistic regression and tree-based techniques to combine the effects of multiple variables to improve the accuracy of predictive. These models have been proven to be effective in predicting outcomes of treatment like the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and will likely become the standard of future medical practice.

The study of depression's underlying mechanisms continues, as well as predictive models based on ML. Recent findings suggest that depression is linked to dysfunctions in specific neural networks. This theory suggests that individual depression treatment food treatment will be based on targeted therapies that target these neural circuits to restore normal function.

Internet-based interventions are an option to achieve this. They can provide more customized and personalized experience lithium for treatment resistant depression patients. For example, one study found that a web-based program was more effective than standard care in alleviating symptoms and ensuring a better quality of life for patients with MDD. A randomized controlled study of a personalized treatment for depression showed that a significant percentage of patients saw improvement over time and fewer side effects.

Predictors of Side Effects

A major challenge in personalized depression treatment involves identifying and predicting which antidepressant medications will cause very little or no side effects. Many patients are prescribed a variety drugs before they find a drug that is both effective and well-tolerated. Pharmacogenetics provides an exciting new way to take an efficient and targeted approach to choosing antidepressant medications.

There are many variables that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of the patient such as ethnicity or gender, and the presence of comorbidities. However, identifying the most reliable and valid factors that can predict the effectiveness of a particular treatment is likely to require randomized controlled trials of considerably larger samples than those typically enrolled in clinical trials. This is because the identifying of interaction effects or moderators may be much more difficult in trials that only consider a single episode of treatment per person, rather than multiple episodes of treatment over a period of time.

In addition to that, predicting a patient's reaction will likely require information on the severity of symptoms, comorbidities and the patient's personal experience of tolerability and effectiveness. There are currently only a few easily measurable sociodemographic variables as well as clinical variables are reliably related to response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to depression treatment is still in its infancy, and many challenges remain. First, it is essential to be able to comprehend and understand the definition of the genetic mechanisms that underlie depression, and an accurate definition of a reliable indicator of the response to treatment. Ethics like privacy, and the responsible use of genetic information are also important to consider. Pharmacogenetics can, in the long run reduce stigma associated with mental health treatment and improve treatment outcomes. But, like any approach to psychiatry careful consideration and implementation is necessary. At present, it's recommended to provide patients with a variety of medications for depression that work and encourage them to speak openly with their physicians.